Gene · 51755
Papers3,441
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,441
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers. | Int J Mol Sci | 2026 | 42589411 | PubTator, text mining | PubMed |
| DNA methylation signatures of sporadic colorectal cancer with microsatellite instability. | Epigenetics | 2026 | 42576420 | PubTator, text mining | PubMed |
| Super-enhancer landscape regulated by CDK12 drives retinoblastoma progression. | Br J Cancer | 2026 | 42547568 | PubTator, text mining | PubMed |
| HER2 overexpression/amplification in colorectal cancer: spatial intratumoral heterogeneity as a key determinant of detection discordance and therapy response. | Virchows Arch | 2026 | 42507169 | PubTator, text mining | PubMed |
| CDK12 mediates the inhibition effect of mechanical unloading on osteoblast proliferation by regulating RNAPII transcription activation. | Bone Joint Res | 2026 | 42486479 | PubTator, text mining | PubMed |
| Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans. | Oncologist | 2026 | 42479142 | PubTator, text mining | PubMed |
| Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery. | Ann Med | 2026 | 42466845 | PubTator, text mining | PubMed |
| Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug. | ACS Med Chem Lett | 2026 | 42445040 | PubTator, text mining | PubMed |
| The distinct molecular profile of metastatic prostate cancer in the mixed Brazilian population. | Genet Med Open | 2026 | 42438725 | PubTator, text mining | PubMed |
| Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States. | Urol Oncol | 2026 | 42431822 | PubTator, text mining | PubMed |
Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype. | Int Urol Nephrol | 2026 | 42423955 | PubTator, text mining | PubMed |
| Evaluation of HER2 status and characteristics by next-generation sequencing in breast cancer. | Front Mol Biosci | 2026 | 42416488 | PubTator, text mining | PubMed |
| Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort. | Cancer Sci | 2026 | 42410894 | PubTator, text mining | PubMed |
| Cyclin K condensates bridge CDK12 to phosphorylate and drive oncogenic YAP activation in hepatocellular carcinoma. | Sci Adv | 2026 | 42397909 | PubTator, text mining | PubMed |
| Germline CDK12 variants in aggressive prostate cancer. | Cancer Discov | 2026 | 42392870 | PubTator, text mining | PubMed |
| A Temporal Phospho-acetylome Atlas of Human Myogenesis Identifies coordinated Post-Translational Regulation. | Mol Cell Proteomics | 2026 | 42392363 | PubTator, text mining | PubMed |
| A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study. | J Natl Cancer Inst | 2026 | 42384930 | PubTator, text mining | PubMed |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | 42376960 | PubTator, text mining | PubMed |
| Prostate Cancer: Etiology, Diagnosis, and Treatment. | Serican J Med | 2026 | 42375929 | PubTator, text mining | PubMed |
| Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. | J Med Chem | 2026 | 42367045 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51755/papers?page=2